Navigation Links
China Ruitai Secures 50 Ton Cellulose Ether Contract from Pharmaceutical Manufacturer
Date:10/13/2010

China Ruitai Secures 50 Ton Cellulose Ether Contract from Pharmaceutical Manufacturer -- FEICHENG, China, Oct. 13 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
OTC, SmallCap, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Chemical, Contracts Click to view news release full screen  

China Ruitai Secures 50 Ton Cellulose Ether Contract from Pharmaceutical Manufacturer

 

FEICHENG, China, Oct. 13 /PRNewswire-Asia-FirstCall/ -- China Ruitai International Holdings Co., Ltd. ("China Ruitai" or the "Company") (OTC Bulletin Board CRUI), a manufacturer and distributor of cellulose ether additives for use in the production of pharmaceuticals, construction materials and adhesives, foods and beverages and cosmetics, announced that it secured a 50 ton cellulose ether contract valued at $0.5 million from ThinFilm, a Shanghai-based pharmaceutical tablet and pill coating company.

"The ThinFilm order is the result of our focus in the pharmaceutical industry where we see the greatest potential for our high-end, high-margin customized cellulose ether products," began Chairman Dianmin Ma of China Ruitai. "As we further concentrate our efforts in the segment, we hope to secure new customers, in addition to a steady flow of reorders for our Rutocel-branded cellulose ethers in China and international markets."

China Ruitai's cellulose ethers cater to a variety of industries in China including the pharmaceutical, packaged food, personal care and cosmetics, and construction industries. Depending on the end product, cellulose ethers are used as coating and binding agent for pharmaceutical drugs, a thickening agent in cosmetics, personal care and foods, a hardening agent for PVC and an adhesive for paints and glues.

As a result of increased demand for the Company's ethyl crystalline ("EC") product line from pharmaceutical customers, the Company has created a dedicated sales department for this sector based in the Company's Feicheng Headquarters in the Shandong province. EC is the Company's highest margin product line and typically sells at 50-plus percent gross margins. Average selling price of China Ruitai's organic, cotton-based cellulose are approximately $12,000 per ton.

About China Ruitai International Holdings Co.

China Ruitai, through its wholly-owned subsidiary, Pacific Capital Group and its majority-owned subsidiary, TaiAn, is engaged in the production, sales, and exportation of deeply processed chemicals, with a primary focus on non- ionic cellulose ether products. Cellulose ether is an organic chemical that dissolves in water and other organic solvents. Due to the surface-active properties of cellulose ether, it acts as a thickener and stabilizer in aqueous solutions, making it a beneficial additive in a wide variety of commercial industries and products, including, but not limited to the pharmaceutical industry, the construction industry, PVC products, food and beverage products, petroleum, and cosmetics. Specific examples of applications in which cellulose ether products are used include: as a stabilizer and thickener in latex paint; in mortar dry mix for building materials; to improve the performance of resin in PVC production; as a membrane reagent, stabilizer, and thickener in pharmaceuticals; and to improve jam, ice cream, toothpaste and lipsticks in the food and cosmetic industries. TaiAn is one of the largest non-ionic cellulose ether producers in China.

Forward-Looking Statements

Certain statements in this release and other written or oral statements made by or on behalf of the Company are "forward-looking statements" within the meaning of the federal securities laws. Statements regarding future events and developments and our future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. The forward-looking statements are subject to a number of risks and uncertainties including market acceptance of the Company's services and projects and the Company's continued access to capital and other risks and uncertainties. The actual results the Company achieves may differ materially from any forward- looking statements due to such risks and uncertainties. These statements are based on our current expectations and speak only as of the date of such statements.

For additional information contact: China Ruitai International Holdings Co., Ltd. Ms. Crystal Tang, VP of Finance 1221 Avenue of Americas Suite 4200 New York, NY 10020. Web: http://www.rutocel.com Tel: +1-212-899-5131 Email: tmqcrui@gmail.com, crystal@rutocel.com HC International, Inc. John Mattio, Senior Vice President 420 Lexington Avenue New York, New York Web: http://www.hcinternational.net Tel: +1-203-616-5144 Email: john.mattio@hcinternational.net
'/>"/>

SOURCE China Ruitai International Holdings Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)...  Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage ... announced new additions to its senior leadership team: ... and Daniel Geffken as interim Chief Financial ... , Pharm.D. has been promoted to Chief Clinical Development ... Doug and Daniel to our management team, as both ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global ... is recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, ... move to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice ...
(Date:1/21/2017)... Pekin, IL (PRWEB) , ... January 21, 2017 , ... ... disorders. Even when individuals experience the freedom of recovery, they often feel shame for ... abuse and post-traumatic stress disorder (PTSD). In the workshop, “Rising Strong in Life After ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and ... essential oils, announced the company had a successful visit to the 2017 ECRM Diet, ... gives companies that work in the nutritional, sports and health industries a chance to ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing in the ... is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of ... asked of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, ...
Breaking Medicine News(10 mins):